Administration of continuous/intermittent olaparib in ovarian cancer patients with a germline BRCA1/2 mutation to determine an optimal dosing schedule for the tablet formulation

J. Mateo, M. Friedlander, C. Sessa, K. Leunen, S. Nicum, C. Gourley, A. Fielding, K. Bowen, S. Kaye, L. R. Molife

Research output: Contribution to journalMeeting abstractpeer-review

Original languageEnglish
Pages (from-to)S161-S161
Number of pages1
JournalEuropean Journal of Cancer
Volume49
Publication statusPublished - Sep 2013
Event17th ECCO / 38th ESMO / 32nd ESTRO European Cancer Congress on Reinforcing Multidisciplinarity - Amsterdam, Netherlands
Duration: 27 Sep 20131 Oct 2013

Cite this